Will hit militant 'safe havens' inside Pakistan, warns Iran

May 8, 2017

Tehran, May 8: The head of the Iranian armed forces warned Islamabad on Monday that Tehran would hit bases inside Pakistan if the government does not confront Sunni militants who carry out cross-border attacks.

militant

Ten Iranian border guards were killed by militants last month. Iran said Jaish al Adl, a Sunni militant group, had shot the guards with long-range guns, fired from inside Pakistan.

The border area has long been plagued by unrest from both drug smuggling gangs and separatist militants.

"We cannot accept the continuation of this situation," Major General Mohammad Baqeri, the head of the Iranian armed forces was quoted as saying by state news agency IRNA.

"We expect the Pakistani officials to control the borders, arrest the terrorists and shut down their bases."

"If the terrorist attacks continue, we will hit their safe havens and cells, wherever they are," he said.

Iran's foreign minister Mohammad Javad Zarif visited Pakistan last week and asked Prime Minister Nawaz Sharif to improve the border security. Pakistan assured Iran it would deploy additional troops along its border.

In 2014 Iran warned it would send troops to Pakistan to retrieve five Iranian border guards kidnapped by Jaish al Adl. Pakistan said at the time that such action would be violation of the international law and warned Iranian forces not to cross the border.

Iran refrained from sending the troops when a local Sunni cleric stepped in and resolved the situation.

Four of the guards were released a few months later, but one was killed by the militants.

Jaish al Adl is a Sunni militant group that has carried out several attacks against Iranian security forces with the aim of highlighting what they say is discrimination against minority Sunni Muslims in Iran, where the majority are Shi'ites.

The group claimed responsibility for attacks that killed eight border guards in April 2015 and 14 border guards in October 2013.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
February 4,2020

Kolkata, Feb 4: A Thailand national on Tuesday gave birth during a flight from Doha to Bangkok.

The unnamed woman passenger went into labour and delivered the baby with the help of a cabin crew of Qatar airways at around 3 am.

The aircraft made the emergency landing in Kolkata and the woman was admitted to a private hospital here. Both the mother and the baby are doing fine.

"An unscheduled flight from Doha to Bangkok QR-830 landed around 03:09 am at Kolkata airport in medical priority landing. The pilot of Qatar flight had asked SOS to ATC for medical priority landing. The flight landed safely, the airport team with the doctor was attending the concerned." Kolkata Airport official said while speaking to news agency.

More details in this regard are awaited.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
May 6,2020

Italian researchers have claimed that they have successfully developed a vaccine to contain coronavirus (COVID-19) which is likely to work on humans, a report said.

Luigi Aurisicchio, CEO of Takis, the firm developing the medication, said that a coronavirus candidate vaccine has neutralised the virus in human cells for the first time, the Arab News reported.

"This is the most advanced stage of testing of a candidate vaccine created in Italy. Human tests are expected after this summer," Aurisicchio was quoted as saying to Italian news agency ANSA.

"According to the Spallanzani Hospital, as far as we know we are the first in the world so far to have demonstrated neutralisation of the coronavirus by a vaccine. We expect this to happen in humans too," he added.

The researchers experimented with the vaccine on mice that had successfully developed antibodies that blocked the virus from infecting the cells. They further observed that the five vaccine candidates generated a large number of antibodies, and selected two with the best results.

All of the vaccine candidates currently being developed are based on the genetic material of DNA protein "spike", the molecular tip used by the coronavirus to enter human cells.

They are injected with the so-called "electroporation" technique, which consists of an intramuscular injection followed by a brief electrical impulse, helping the vaccine break into the cells and activating the immune system, the report said.

Researchers believe that this makes their vaccine particularly effective for generating functional antibodies against the "spike" protein, in particular in the lung cells, which are the most vulnerable to coronavirus.

"We are working hard for a vaccine coming from Italian research, with an all-Italian and innovative technology, tested in Italy and made available to everyone," Aurisicchio was quoted by the Arab News report.

"In order to reach this goal, we need the support of national and international institutions and partners who may help us speed up the process," he noted.

The total number of COVID-19 infections, fatalities and recoveries since the pandemic began has risen to 213,013 in the country.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
July 29,2020

If everything goes as Russia’s expectation, it will be world’s first country to approve a coronavirus vaccine for widespread in the second week of August despite safety and efficacy concerns, according to a report. The adenoviral vector-based vaccine developed by Russian military and government researchers is currently in phase 2 trials.

According to a report from CNN, Russian officials are hoping to get approval for the COVID-19 vaccine developed by the Moscow-based Gamaleya Institute on Agust 10 or even before that. The officials told the outlet that the vaccine will be approved for public use with frontline healthcare workers receiving it first.

“It’s a Sputnik moment,” said Kirill Dmitriev, head of Russia’s sovereign wealth fund, which is financing Russian vaccine research, referring to the successful 1957 launch of the world’s first satellite by the Soviet Union, according to CNN.

“Americans were surprised when they heard Sputnik’s beeping. It’s the same with this vaccine. Russia will have got there first,” he was quoted as saying.

However, Russia is yet to release the scientific data on its coronavirus vaccine trials, hence, questions remain about the safety and efficacy of the vaccine, said the report. The vaccine is in the second phase of testing with developers planning to launch the phase 3 trials sometime after August 3.

Earlier, Interfax reported, citing Health Minister Mikhail Murashko, that the vaccine will be widely used in parallel with phase 3 trials. He said the country plans to vaccinate medics who are at high-risk for COVID-19 next month before clinical trials are completed.

Murashko added that individuals at higher risk of getting infected with the coronavirus such as older people or those with health conditions will also be prioritised for the vaccine, although he did not estimate or reveal when that would happen. The minister added 800 people will be recruited for the phase 3 trials.

Meanwhile, health officials were more cautious considering the fact that human testing of the vaccine is incomplete, and the state registration is expected to begin after August 3, reported The Moscow Times.

On Monday, Moderna and Pfizer announced the commencement of the final phase 3 trials of their candidate vaccines against the SARS-CoV-2 virus, which has so far claimed at least 654,477 lives and infected 16,514,500 people worldwide. 

Researchers will recruit up to 30,000 volunteers in separate trials both backed by the US government. India's first indigenous coronavirus vaccine, COVAXIN, is undergoing phase 1 human clinical trials across the country. More than 150 COVID-19 vaccines are being developed all over the world with at least six candidates already in late-stage clinical trials.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.